Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future

References

• Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 1996;85(3):299-302
   PubMed Web of Science ®Google Scholar
• Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005;23:683-747
   PubMed Web of Science ®Google Scholar
• Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000;343(13):938-52
   PubMed Web of Science ®Google Scholar
• Weiner HL. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann Neurol 2009;65(3):239-48
   PubMed Web of Science ®Google Scholar
• Hafler DA. Multiple sclerosis. J Clin Invest 2004;113(6):788-94
   PubMed Web of Science ®Google Scholar
• Damal K, Stoker E, Foley JF. Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action. Biologics 2013;7:247-58
   PubMedGoogle Scholar
• Poonawalla AH, Datta S, Juneja V, et al. Composite MRI scores improve correlation with EDSS in multiple sclerosis. Mult Scler 2010;16(9):1117-25
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33(11):1444-52
   PubMed Web of Science ®Google Scholar
• Lourenco P, Shirani A, Saeedi J, et al. Oligoclonal bands and cerebrospinal fluid markers in multiple sclerosis: associations with disease course and progression. Mult Scler 2012
   PubMed Web of Science ®Google Scholar
• Bakshi R, Thompson AJ, Rocca MA, et al. MRI in multiple sclerosis: current status and future prospects. Lancet Neurol 2008;7(7):615-25
   PubMed Web of Science ®Google Scholar
• Tourdias T, Dousset V. Neuroinflammatory Imaging Biomarkers: Relevance to Multiple Sclerosis and its Therapy. Neurotherapeutics 2012
   Web of Science ®Google Scholar
• Filippi M, Agosta F. Imaging biomarkers in multiple sclerosis. J Magn Reson Imaging 2010;31(4):770-88
   PubMed Web of Science ®Google Scholar
• Neema M, Stankiewicz J, Arora A, et al.I in multiple sclerosis: what’s inside the toolbox? Neurotherapeutics 2007;4(4):602-17
   PubMed Web of Science ®Google Scholar
• Sargento-Freitas J, Batista S, Macario C, et al. Clinical predictors of an optimal response to natalizumab in multiple sclerosis. J Clin Neurosci 2013;20(5):659-62
   PubMed Web of Science ®Google Scholar
• Rio J, Comabella M, Montalban X. Predicting responders to therapies for multiple sclerosis. Nat Rev Neurol 2009;5(10):553-60
   PubMed Web of Science ®Google Scholar
• Sormani MP, De Stefano N. Defining and scoring response to IFN-beta in multiple sclerosis. Nature reviews. Neurology 2013;9(9):504-12
   PubMed Web of Science ®Google Scholar
• Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69(2):292-302
   PubMed Web of Science ®Google Scholar
• Freedman MS. Long-term follow-up of clinical trials of multiple sclerosis therapies. Neurology 2011;76(1 Suppl 1):S26-34
   PubMed Web of Science ®Google Scholar
• Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13(3):227-31
   PubMed Web of Science ®Google Scholar
• Biomarkers Definitions Working G. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69(3):89-95
   PubMed Web of Science ®Google Scholar
• Katz R. Biomarkers and surrogate markers: an FDA perspective. Neuro 2004;1(2):189-95
   Google Scholar
• Ziemann U, Wahl M, Hattingen E, Tumani H. Development of biomarkers for multiple sclerosis as a neurodegenerative disorder. Prog Neurobiol 2011;95(4):670-85
   PubMed Web of Science ®Google Scholar
• Gomes Mda M, Engelhardt E. Jean-Martin Charcot, father of modern neurology: an homage 120 years after his death. Arq Neuropsiquiatr 2013;71(10):815-17
   PubMed Web of Science ®Google Scholar
• Carswell R. Pathological anatomy. Illustrations of the elementary forms of disease (Longman, Orme, Brown, Green and Longman, London; 1838
   Google Scholar
• Compston A. The 150th anniversary of the first depiction of the lesions of multiple sclerosis. J Neurol Neurosurg Psychiatry 1988;51(10):1249-52
   PubMed Web of Science ®Google Scholar
• Talley CL. A history of multiple sclerosis. Praeger; Westport: Conn: 2008
   Google Scholar
• Tsafrir I, Guedeau-Boudeville MA, Kandel D, Stavans J. Coiling instability of multilamellar membrane tubes with anchored polymers. Phys Rev E Stat Nonlin Soft Matter Phys 2001;63(3 Pt 1):031603
   PubMed Web of Science ®Google Scholar
• Rivers TM, Sprunt DH, Berry GP. Observations on attempts to produce acute disseminated encephalomyelitis in monkeys. J Exp Med 1933;58(1):39-53
   PubMedGoogle Scholar
• Schwentker FF, Rivers TM. The antibody response of rabbits to injections of emulsions and extracts of homologous brain. J Exp Med 1934;60(5):559-74
   PubMedGoogle Scholar
• Rivers TM, Schwentker FF. Encephalomyelitis accompanied by myelin destruction experimentally produced in monkeys. J Exp Med 1935;61(5):689-702
   PubMedGoogle Scholar
• Hurst EW. The effects of the injection of normal brain emulsion into rabbits, with special reference to the aetiology of the paralytic accidents of antirabic treatment. J Hyg (Lond) 1932;32(1):33-44
   PubMedGoogle Scholar
• Morgan IM. Allergic encephalomyelitis in monkeys in response to injection of normal monkey nervous tissue. J Exp Med 1947;85(1):131-40
   PubMed Web of Science ®Google Scholar
• Kabat EA, Wolf A, Bezer AE. The rapid production of acute disseminated encephalomyelitis in Rhesus monkeys by injection of heterologous and homologous brain tissue with adjuvants. J Exp Med 1947;85(1):117-30
   PubMed Web of Science ®Google Scholar
• Robinson AP, Harp CT, Noronha A, Miller SD. The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment. Handb Clin Neurol 2014;122:173-89
   PubMedGoogle Scholar
• Steinman L. Optic neuritis, a new variant of experimental encephalomyelitis, a durable model for all seasons, now in its seventieth year. J Exp Med 2003;197(9):1065-71
   PubMed Web of Science ®Google Scholar
• Kabat EA, Moore DH, Landow H. An electrophoretic study of the protein components in cerebrospinal fluid and their relationship to the serum proteins. J Clin Invest 1942;21(5):571-7
   PubMedGoogle Scholar
• Green F. The colloidal gold reaction of the cerebrospinal fluid. Can Med Assoc J 1925;15(11):1139-43
   PubMedGoogle Scholar
• McDiarmid N. The value of routine examination of the cerebrospinal fluid: report on the examination of 3,200 fluids. J Neurol Psychopathol 1931;11(43):247-54
   PubMedGoogle Scholar
• Kabat EA, Glusman M, Knaub V. Quantitative estimation of the albumin and gamma globulin in normal and pathologic cerebrospinal fluid by immunochemical methods. Am J Med 1948;4(5):653-62
   PubMed Web of Science ®Google Scholar
• Lowenthal A, Vansande M, Karcher D. The differential diagnosis of neurological diseases by fractionating electrophoretically the CSF gamma-globulins. J Neurochem 1960;6:51-6
   PubMed Web of Science ®Google Scholar
• Davenport RD, Keren DF. Oligoclonal bands in cerebrospinal fluids: significance of corresponding bands in serum for diagnosis of multiple sclerosis. Clin Chem 1988;34(4):764-5
   PubMed Web of Science ®Google Scholar
• Young IR, Hall AS, Pallis CA, et al. Nuclear magnetic resonance imaging of the brain in multiple sclerosis. Lancet 1981;2(8255):1063-6
   PubMed Web of Science ®Google Scholar
• Gajofatto A, Calabrese M, Benedetti MD, Monaco S. Clinical, MRI, and CSF markers of disability progression in multiple sclerosis. Dis Markers 2013;35(6):687-99
   PubMed Web of Science ®Google Scholar
• Olek MJ. Multiple sclerosis: etiology, diagnosis, and new treatment strategies. Humana Press; Totowa, N.J: 2005
   Google Scholar
• Schumacker GA, Beebe G, Kibler RF, et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann N Y Acad Sci 1965;122:552-68
   PubMed Web of Science ®Google Scholar
• Miller DH, Weinshenker BG, Filippi M, et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 2008;14(9):1157-74
   PubMed Web of Science ®Google Scholar
• McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50(1):121-7
   PubMed Web of Science ®Google Scholar
• Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘McDonald Criteria’. Ann Neurol 2005;58(6):840-6
   PubMed Web of Science ®Google Scholar
• Milo R, Miller A. Revised diagnostic criteria of multiple sclerosis. Autoimmun Rev 2014;13(4-5):518-24
   PubMed Web of Science ®Google Scholar
• Stangel M, Fredrikson S, Meinl E, et al. The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. Nat Rev Neurol 2013;9(5):267-76
   PubMed Web of Science ®Google Scholar
• Tumani H, Deisenhammer F, Giovannoni G, et al. Revised McDonald criteria: the persisting importance of cerebrospinal fluid analysis. Ann Neurol 2011;70(3):520; author reply 521
   PubMed Web of Science ®Google Scholar
• Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014;83(3):278-86
   PubMed Web of Science ®Google Scholar
• Cross AH, Wingerchuk DM, Weinshenker BG. Active and progressive: a new duality of MS classification. Neurology 2014;83(3):206-7
   PubMed Web of Science ®Google Scholar
• Chen K, Rajewsky N. The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet 2007;8(2):93-103
   PubMed Web of Science ®Google Scholar
• O’Connell RM, Rao DS, Baltimore D. MicroRNA regulation of inflammatory responses. Annu Rev Immunol 2012;30:295-312
   PubMed Web of Science ®Google Scholar
• Baumjohann D, Ansel KM. MicroRNA-mediated regulation of T helper cell differentiation and plasticity. Nat Reviews Immunol 2013;13(9):666-78
   PubMed Web of Science ®Google Scholar
• Liu NK, Xu XM. MicroRNA in central nervous system trauma and degenerative disorders. Physiol Genomics 2011;43(10):571-80
   PubMed Web of Science ®Google Scholar
• Moreno-Moya JM, Vilella F, Simon C. MicroRNA: key gene expression regulators. Fertil Steril 2014;101(6):1516-23
   PubMed Web of Science ®Google Scholar
• Rao P, Benito E, Fischer A. MicroRNAs as biomarkers for CNS disease. Front Mol Neurosci 2013;6:39
   PubMed Web of Science ®Google Scholar
• Otaegui D, Baranzini SE, Armananzas R, et al. Differential micro RNA expression in PBMC from multiple sclerosis patients. PLoS One 2009;4(7):e6309
   PubMed Web of Science ®Google Scholar
• Lindberg RL, Hoffmann F, Mehling M, et al. Altered expression of miR-17-5p in CD4+ lymphocytes of relapsing-remitting multiple sclerosis patients. Eur J Immunol 2010;40(3):888-98
   PubMed Web of Science ®Google Scholar
• Keller A, Leidinger P, Lange J, et al. Multiple sclerosis: microRNA expression profiles accurately differentiate patients with relapsing-remitting disease from healthy controls. PLoS One 2009;4(10):e7440
   PubMed Web of Science ®Google Scholar
• Siegel SR, Mackenzie J, Chaplin G, et al. Circulating microRNAs involved in multiple sclerosis. Mol Biol Rep 2012;39(5):6219-25
   PubMed Web of Science ®Google Scholar
• Fenoglio C, Ridolfi E, Cantoni C, et al. Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis. Mult Scler 2013;19(14):1938-42
   PubMed Web of Science ®Google Scholar
• Ridolfi E, Fenoglio C, Cantoni C, et al. Expression and genetic analysis of microRNAs involved in multiple sclerosis. Int J Mol Sci 2013;14(3):4375-84
   PubMed Web of Science ®Google Scholar
• Du C, Liu C, Kang J, et al. MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat Immunol 2009;10(12):1252-9
   PubMed Web of Science ®Google Scholar
• Junker A, Krumbholz M, Eisele S, et al. MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain 2009;132(Pt 12):3342-52
   PubMed Web of Science ®Google Scholar
• Cox MB, Cairns MJ, Gandhi KS, et al. MicroRNAs miR-17 and miR-20a inhibit T cell activation genes and are under-expressed in MS whole blood. PLoS One 2010;5(8):e12132
   PubMed Web of Science ®Google Scholar
• Sievers C, Meira M, Hoffmann F, et al. Altered microRNA expression in B lymphocytes in multiple sclerosis: towards a better understanding of treatment effects. Clinical immunology 2012;144(1):70-9
   PubMed Web of Science ®Google Scholar
• Haghikia A, Haghikia A, Hellwig K, et al. Regulated microRNAs in the CSF of patients with multiple sclerosis: a case-control study. Neurology 2012;79(22):2166-70
   PubMed Web of Science ®Google Scholar
• Guerau-de-Arellano M, Smith KM, Godlewski J, et al. Micro-RNA dysregulation in multiple sclerosis favours pro-inflammatory T-cell-mediated autoimmunity. Brain 2011;134(Pt 12):3578
   PubMed Web of Science ®Google Scholar
• Thamilarasan M, Koczan D, Hecker M, et al. MicroRNAs in multiple sclerosis and experimental autoimmune encephalomyelitis. Autoimmun Rev 2012;11(3):174-9
   PubMed Web of Science ®Google Scholar
• O’Connell RM, Taganov KD, Boldin MP, et al. MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci USA 2007. 104(5):1604-9
   Google Scholar
• Wu X, Fan W, Fang R, Wu G. Regulation of microRNA-155 in endothelial inflammation by targeting nuclear factor (NF)-kappaB P65. J Cell Biochem 2014;115(11):1928-36
   PubMed Web of Science ®Google Scholar
• Chen F, Hu SJ. Effect of microRNA-34a in cell cycle, differentiation, and apoptosis: a review. J Biochem Mol Toxicol 2012;26(2):79-86
   PubMed Web of Science ®Google Scholar
• Schmidt H, Williamson D, Ashley-Koch A. HLA-DR15 haplotype and multiple sclerosis: a HuGE review. Am J Epidemiol 2007;165(10):1097-109
   PubMed Web of Science ®Google Scholar
• Kim RY, Xu H, Myllykangas S, Ji H. Genetic-based biomarkers and next-generation sequencing: the future of personalized care in colorectal cancer. Personalized medicine 2011;8(3):331-45
   PubMed Web of Science ®Google Scholar
• Comabella M, Martin R. Genomics in multiple sclerosis-current state and future directions. J Neuroimmunol 2007;187(1-2):1-8
   PubMed Web of Science ®Google Scholar
• Achiron A, Gurevich M. Peripheral blood gene expression signature mirrors central nervous system disease: the model of multiple sclerosis. Autoimmun Rev 2006;5(8):517-22
   PubMed Web of Science ®Google Scholar
• Bomprezzi R, Ringner M, Kim S, et al. Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. Hum Mol Genet 2003;12(17):2191-9
   PubMed Web of Science ®Google Scholar
• Zuvich RL, McCauley JL, Oksenberg JR, et al. Genetic variation in the IL7RA/IL7 pathway increases multiple sclerosis susceptibility. Hum Genet 2010;127(5):525-35
   PubMed Web of Science ®Google Scholar
• Achiron A, Feldman A, Mandel M, Gurevich M. Impaired expression of peripheral blood apoptotic-related gene transcripts in acute multiple sclerosis relapse. Ann N Y Acad Sci 2007;1107:155-67
   PubMed Web of Science ®Google Scholar
• Brynedal B, Khademi M, Wallstrom E, et al. Gene expression profiling in multiple sclerosis: a disease of the central nervous system, but with relapses triggered in the periphery? Neurobiol Dis 2010;37(3):613-21
   PubMed Web of Science ®Google Scholar
• Booth DR, Arthur AT, Teutsch SM, et al. Gene expression and genotyping studies implicate the interleukin 7 receptor in the pathogenesis of primary progressive multiple sclerosis. J Mol Med 2005;83(10):822-30
   PubMed Web of Science ®Google Scholar
• Hecker M, Paap BK, Goertsches RH, et al. Reassessment of blood gene expression markers for the prognosis of relapsing-remitting multiple sclerosis. PLoS One 2011;6(12):e29648
   PubMed Web of Science ®Google Scholar
• Satoh J, Nakanishi M, Koike F, et al. Microarray analysis identifies an aberrant expression of apoptosis and DNA damage-regulatory genes in multiple sclerosis. Neurobiol Dis 2005;18(3):537-50
   PubMed Web of Science ®Google Scholar
• Romme-Christensen J, Bornsen L, Hesse D, et al. Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis. J Neuroinflammation 2012;9:215
   PubMed Web of Science ®Google Scholar
• Hecker M, Goertsches RH, Fatum C, et al. Network analysis of transcriptional regulation in response to intramuscular interferon-beta-1a multiple sclerosis treatment. Pharmacogenomics J 2012;12(4):360
   PubMed Web of Science ®Google Scholar
• Hecker M, Goertsches RH, Fatum C, et al. Network analysis of transcriptional regulation in response to intramuscular interferon-beta-1a multiple sclerosis treatment. Pharmacogenomics J 2012;12(2):134-46
   PubMed Web of Science ®Google Scholar
• Goertsches RH, Hecker M, Koczan D, et al. Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-beta-1b treatment in relapsing remitting MS. Pharmacogenomics 2010;11(2):147-61
   PubMed Web of Science ®Google Scholar
• Serrano-Fernandez P, Moller S, Goertsches R, et al. Time course transcriptomics of IFNB1b drug therapy in multiple sclerosis. Autoimmunity 2010;43(2):172-8
   PubMed Web of Science ®Google Scholar
• Singh MK, Scott TF, LaFramboise WA, et al. Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing beta-interferon therapy. J Neurol Sci 2007;258(1-2):52-9
   PubMed Web of Science ®Google Scholar
• Sturzebecher S, Wandinger KP, Rosenwald A, et al. Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain 2003;126(Pt 6):1419-29
   PubMedGoogle Scholar
• Weinstock-Guttman B, Badgett D, Patrick K, et al. Genomic effects of IFN-beta in multiple sclerosis patients. J Immunol 2003;171(5):2694-702
   PubMed Web of Science ®Google Scholar
• Hong J, Zang YC, Hutton G, et al. Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis. J Neuroimmunol 2004;152(1-2):126-39
   PubMed Web of Science ®Google Scholar
• Achiron A, Feldman A, Gurevich M. Molecular profiling of glatiramer acetate early treatment effects in multiple sclerosis. Dis Markers 2009;27(2):63-73
   PubMed Web of Science ®Google Scholar
• Khademi M, Bornsen L, Rafatnia F, et al. The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers. Eur J Neurol 2009;16(4):528-36
   PubMed Web of Science ®Google Scholar
• von Wussow P, Jakschies D, Hochkeppel HK, et al. The human intracellular Mx-homologous protein is specifically induced by type I interferons. Eur J Immunol 1990;20(9):2015-19
   PubMed Web of Science ®Google Scholar
• Killestein J, Polman CH. Determinants of interferon beta efficacy in patients with multiple sclerosis. Nature reviews. Neurology 2011;7(4):221-8
   PubMed Web of Science ®Google Scholar
• Bertolotto A, Gilli F, Sala A, et al. Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. J Immunol Methods 2001;256(1-2):141-52
   PubMed Web of Science ®Google Scholar
• Pachner AR, Bertolotto A, Deisenhammer F. Measurement of MxA mRNA or protein as a biomarker of IFNbeta bioactivity: detection of antibody-mediated decreased bioactivity (ADB). Neurology 2003;61(9 Suppl 5):S24-6
   PubMed Web of Science ®Google Scholar
• Malucchi S, Gilli F, Caldano M, et al. Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology 2008;70(13 Pt 2):1119-1127
   PubMed Web of Science ®Google Scholar
• Lindberg RL, Kappos L. Transcriptional profiling of multiple sclerosis: towards improved diagnosis and treatment. Expert Rev Mol Diagn 2006;6(6):843-55
   PubMed Web of Science ®Google Scholar
• Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002;1(11):845-67
   PubMed Web of Science ®Google Scholar
• Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006;24(8):971-83
   PubMed Web of Science ®Google Scholar
• Tian Y, Apperson ML, Ander BP, et al. Differences in exon expression and alternatively spliced genes in blood of multiple sclerosis compared to healthy control subjects. J Neuroimmunol 2011;230(1-2):124-9
   PubMed Web of Science ®Google Scholar
• Sanchez-Pla A, Reverter F, Ruiz de Villa MC, Comabella M. Transcriptomics: mRNA and alternative splicing. J Neuroimmunol 2012;248(1-2):23-31
   PubMed Web of Science ®Google Scholar
• Adibhatla RM, Hatcher JF. Altered lipid metabolism in brain injury and disorders. Subcell Biochem 2008;49:241-68
   PubMedGoogle Scholar
• Giubilei F, Antonini G, Di Legge S, et al. Blood cholesterol and MRI activity in first clinical episode suggestive of multiple sclerosis. Acta Neurol Scand 2002;106(2):109-12
   PubMed Web of Science ®Google Scholar
• Bretillon L, Siden A, Wahlund LO, et al. Plasma levels of 24S-hydroxycholesterol in patients with neurological diseases. Neurosci Lett 2000;293(2):87-90
   PubMed Web of Science ®Google Scholar
• Quintana FJ, Yeste A, Weiner HL, Covacu R. Lipids and lipid-reactive antibodies as biomarkers for multiple sclerosis. J Neuroimmunol 2012;248(1-2):53-7
   PubMed Web of Science ®Google Scholar
• Leoni V. Oxysterols as markers of neurological disease-a review. Scand J Clin Lab Invest 2009;69(1):22-5
   PubMed Web of Science ®Google Scholar
• Dietschy JM, Turley SD. Thematic review series: brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res 2004;45(8):1375-97
   PubMed Web of Science ®Google Scholar
• Leoni V, Caccia C. Oxysterols as biomarkers in neurodegenerative diseases. Chem Phys Lipids 2011;164(6):515-24
   PubMed Web of Science ®Google Scholar
• Ramsey RB, Nicholas HJ. Unusual urinary cholesterol metabolites following intracerebral injection of [4-14C]cholesterol into rats: I. The minor 14C-metabolite. Lipids 1982;17(3):263-7
   PubMed Web of Science ®Google Scholar
• Nicholas HJ, Taylor J. Central nervous system demyelinating diseases and increased release of cholesterol into the urinary system of rats. Lipids 1994;29(9):611-17
   PubMed Web of Science ®Google Scholar
• Shore VG, Smith ME, Perret V, Laskaris MA. Alterations in plasma lipoproteins and apolipoproteins in experimental allergic encephalomyelitis. J Lipid Res 1987;28(2):119-29
   PubMed Web of Science ®Google Scholar
• Weinstock-Guttman B, Zivadinov R, Mahfooz N, et al. Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. J Neuroinflammation 2011;8:127
   PubMed Web of Science ®Google Scholar
• Subedi BH, Joshi PH, Jones SR, et al. Current guidelines for high-density lipoprotein cholesterol in therapy and future directions. Vasc Health Risk Manag 2014;10:205-16
   PubMedGoogle Scholar
• Ciurleo R, Bramanti P, Marino S. Role of statins in the treatment of multiple sclerosis. Pharmacol Res 2014;87:133-43
   PubMed Web of Science ®Google Scholar
• Leoni V, Masterman T, Diczfalusy U, et al. Changes in human plasma levels of the brain specific oxysterol 24S-hydroxycholesterol during progression of multiple sclerosis. Neurosci Lett 2002;331(3):163-6
   PubMed Web of Science ®Google Scholar
• Karrenbauer VD, Leoni V, Lim ET, et al. Plasma cerebrosterol and magnetic resonance imaging measures in multiple sclerosis. Clin Neurol Neurosurg 2006;108(5):456-60
   PubMed Web of Science ®Google Scholar
• Teunissen CE, Dijkstra CD, Polman CH, et al. Decreased levels of the brain specific 24S-hydroxycholesterol and cholesterol precursors in serum of multiple sclerosis patients. Neurosci Lett 2003;347(3):159-62
   PubMed Web of Science ®Google Scholar
• Teunissen CE, Floris S, Sonke M, et al. 24S-hydroxycholesterol in relation to disease manifestations of acute experimental autoimmune encephalomyelitis. J Neurosci Res 2007;85(7):1499-505
   PubMed Web of Science ®Google Scholar
• Leoni V, Caccia C. Potential diagnostic applications of side chain oxysterols analysis in plasma and cerebrospinal fluid. Biochem Pharmacol 2013;86(1):26-36
   PubMed Web of Science ®Google Scholar
• Smith KJ, Kapoor R, Felts PA. Demyelination: the role of reactive oxygen and nitrogen species. Brain pathology 1999;9(1):69-92
   PubMed Web of Science ®Google Scholar
• Chang JY, Liu LZ. Neurotoxicity of cholesterol oxides on cultured cerebellar granule cells. Neurochem Int 1998;32(4):317-23
   PubMed Web of Science ®Google Scholar
• Chang JY, Phelan KD, Chavis JA. Neurotoxicity of 25-OH-cholesterol on sympathetic neurons. Brain Res Bull 1998;45(6):615-22
   PubMed Web of Science ®Google Scholar
• Chang JY, Phelan KD, Liu LZ. Neurotoxicity of 25-OH-cholesterol on NGF-differentiated PC12 cells. Neurochem Res 1998;23(1):7-16
   PubMed Web of Science ®Google Scholar
• Diestel A, Aktas O, Hackel D, et al. Activation of microglial poly(ADP-ribose)-polymerase-1 by cholesterol breakdown products during neuroinflammation: a link between demyelination and neuronal damage. J Exp Med 2003;198(11):1729-40
   PubMed Web of Science ®Google Scholar
• Leoni V, Lutjohann D, Masterman T. Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis. J Lipid Res 2005;46(2):191-5
   PubMed Web of Science ®Google Scholar
• Farez MF, Quintana FJ, Gandhi R, et al. Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE. Nat Immunol 2009;10(9):958-64
   PubMed Web of Science ®Google Scholar
• Haider L, Fischer MT, Frischer JM, et al. Oxidative damage in multiple sclerosis lesions. Brain 2011;134(Pt 7):1914-24
   PubMed Web of Science ®Google Scholar
• Sbardella E, Greco A, Stromillo ML, et al. Isoprostanes in clinically isolated syndrome and early multiple sclerosis as biomarkers of tissue damage and predictors of clinical course. Mult Scler 2013;19(4):411-17
   PubMed Web of Science ®Google Scholar
• Teunissen CE, Sombekke M, van Winsen L, et al. Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression. Mult Scler 2012;18(8):1092-8
   PubMed Web of Science ®Google Scholar
• Miller E, Mrowicka M, Saluk-Juszczak J, Ireneusz M. The level of isoprostanes as a non-invasive marker for in vivo lipid peroxidation in secondary progressive multiple sclerosis. Neurochem Res 2011;36(6):1012-16
   PubMed Web of Science ®Google Scholar
• Koch M, Mostert J, Arutjunyan AV, et al. Plasma lipid peroxidation and progression of disability in multiple sclerosis. Eur J Neurol 2007;14(5):529-33
   PubMed Web of Science ®Google Scholar
• Greco A, Minghetti L, Puopolo M, et al. Cerebrospinal fluid isoprostanes are not related to inflammatory activity in relapsing-remitting multiple sclerosis. J Neurol Sci 2004;224(1-2):23-7
   PubMed Web of Science ®Google Scholar
• Naidoo R, Knapp ML. Studies of lipid peroxidation products in cerebrospinal fluid and serum in multiple sclerosis and other conditions. Clin Chem 1992;38(12):2449-54
   PubMed Web of Science ®Google Scholar
• Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005;5(11):845-56
   PubMed Web of Science ®Google Scholar
• Howes JM, Keen JN, Findlay JB, Carter AM. The application of proteomics technology to thrombosis research: the identification of potential therapeutic targets in cardiovascular disease. Diab Vasc Dis Res 2008;5(3):205-12
   PubMed Web of Science ®Google Scholar
• van Venrooij WJ, Vossenaar ER, Zendman AJ. Anti-CCP antibodies: the new rheumatoid factor in the serology of rheumatoid arthritis. Autoimmun Rev 2004(3 Suppl 1):S17-19
   PubMedGoogle Scholar
• von Muhlen CA, Tan EM. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum 1995;24(5):323-58
   PubMed Web of Science ®Google Scholar
• Berger JR, Dean D. Neurosyphilis. Handb Clin Neurol 2014;121:1461-72
   PubMedGoogle Scholar
• Kherad O, Kaiser L, Bridevaux PO, et al. Upper-respiratory viral infection, biomarkers, and COPD exacerbations. Chest 2010;138(4):896-904
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Revised guidelines for HIV counseling, testing, and referral. MMWR. Recomm Rep 2001;50(RR-19):1-57. quiz CE51-19a51-CE56-19a51
   Google Scholar
• Jaros JA, Guest PC, Bahn S, Martins-de-Souza D. Affinity depletion of plasma and serum for mass spectrometry-based proteome analysis. Methods Mol Biol 2013;1002:1-11
   PubMedGoogle Scholar
• Rodriguez-Rodriguez A, Egea-Guerrero JJ, Leon-Justel A, et al. Role of S100B protein in urine and serum as an early predictor of mortality after severe traumatic brain injury in adults. Clin Chim Acta 2012;414:228-33
   PubMed Web of Science ®Google Scholar
• Muraro PA, Leist T, Bielekova B, McFarland HF. VLA-4/CD49d downregulated on primed T lymphocytes during interferon-beta therapy in multiple sclerosis. J Neuroimmunol 2000;111(1-2):186-94
   PubMed Web of Science ®Google Scholar
• Schiott A, Lindstedt M, Johansson-Lindbom B, et al.27- CD4+ memory T cells define a differentiated memory population at both the functional and transcriptional levels. Immunology 2004;113(3):363-70
   PubMed Web of Science ®Google Scholar
• Zafranskaya M, Oschmann P, Engel R, et al. Interferon-beta therapy reduces CD4+ and CD8+ T-cell reactivity in multiple sclerosis. Immunology 2007;121(1):29-39
   PubMed Web of Science ®Google Scholar
• Chatzimanolis N, Kraus J, Bauer R, et al. CD45RA+ ICAM-3+ lymphocytes in interferon-beta1b-treated and -untreated patients with relapsing-remitting multiple sclerosis. Acta Neurol Scand 2004;110(6):377-85
   PubMed Web of Science ®Google Scholar
• Wang HY, Matsui M, Araya S, et al. Immune parameters associated with early treatment effects of high-dose intravenous methylprednisolone in multiple sclerosis. J Neurol Sci 2003;216(1):61-6
   PubMed Web of Science ®Google Scholar
• Franciotta DM, Grimaldi LM, Martino GV, et al. Tumor necrosis factor in serum and cerebrospinal fluid of patients with multiple sclerosis. Ann Neurol 1989;26(6):787-9
   PubMed Web of Science ®Google Scholar
• Sharief MK, Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 1991;325(7):467-72
   PubMed Web of Science ®Google Scholar
• Drulovic J, Mostarica-Stojkovic M, Levic Z, et al. Interleukin-12 and tumor necrosis factor-alpha levels in cerebrospinal fluid of multiple sclerosis patients. J Neurol Sci 1997;147(2):145-50
   PubMed Web of Science ®Google Scholar
• Vladic A, Horvat G, Vukadin S, et al. Cerebrospinal fluid and serum protein levels of tumour necrosis factor-alpha (TNF-alpha) interleukin-6 (IL-6) and soluble interleukin-6 receptor (sIL-6R gp80) in multiple sclerosis patients. Cytokine 2002;20(2):86-9
   PubMed Web of Science ®Google Scholar
• Stelmasiak Z, Koziol-Montewka M, Dobosz B, et al. Interleukin-6 concentration in serum and cerebrospinal fluid in multiple sclerosis patients. Med Sci Monit 2000;6(6):1104-8
   PubMedGoogle Scholar
• Malmestrom C, Andersson BA, Haghighi S, Lycke J. IL-6 and CCL2 levels in CSF are associated with the clinical course of MS: implications for their possible immunopathogenic roles. J Neuroimmunol 2006;175(1-2):176-82
   PubMed Web of Science ®Google Scholar
• Chen YC, Yang X, Miao L, et al. Serum level of interleukin-6 in Chinese patients with multiple sclerosis. J Neuroimmunol 2012;249(1-2):109-11
   PubMed Web of Science ®Google Scholar
• Zepp J, Wu L, Li X. IL-17 receptor signaling and T helper 17-mediated autoimmune demyelinating disease. Trends Immunol 2011;32(5):232-9
   PubMed Web of Science ®Google Scholar
• Axtell RC, de Jong BA, Boniface K, et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 2010;16(4):406-12
   PubMed Web of Science ®Google Scholar
• Lee LF, Axtell R, Tu GH, et al. IL-7 promotes T(H)1 development and serum IL-7 predicts clinical response to interferon-beta in multiple sclerosis. Sci Transl Med 2011;3(93):93ra68
   PubMed Web of Science ®Google Scholar
• Balasa R, Bajko Z, Hutanu A. Serum levels of IL-17A in patients with relapsing-remitting multiple sclerosis treated with interferon-beta. Mult Scler 2013;19(7):885-90
   PubMed Web of Science ®Google Scholar
• Hartung HP, Steinman L, Goodin DS, et al. Interleukin 17F level and interferon beta response in patients with multiple sclerosis. JAMA Neurol 2013;70(8):1017-21
   PubMed Web of Science ®Google Scholar
• Maimone D, Gregory S, Arnason BG, Reder AT. Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunol 1991;32(1):67-74
   PubMed Web of Science ®Google Scholar
• Rentzos M, Cambouri C, Rombos A, et al. IL-15 is elevated in serum and cerebrospinal fluid of patients with multiple sclerosis. J Neurol Sci 2006;241(1-2):25-9
   PubMed Web of Science ®Google Scholar
• Nguyen LT, Ramanathan M, Weinstock-Guttman B, et al. Sex differences in in vitro pro-inflammatory cytokine production from peripheral blood of multiple sclerosis patients. J Neurol Sci 2003;209(1-2):93-9
   PubMed Web of Science ®Google Scholar
• Nicoletti F, Patti F, Cocuzza C, et al. Elevated serum levels of interleukin-12 in chronic progressive multiple sclerosis. J Neuroimmunol 1996;70(1):87-90
   PubMed Web of Science ®Google Scholar
• Chen YC, Chen SD, Miao L, et al. Serum levels of interleukin (IL)-18, IL-23 and IL-17 in Chinese patients with multiple sclerosis. J Neuroimmunol 2012;243(1-2):56-60
   PubMed Web of Science ®Google Scholar
• Krumbholz M, Theil D, Cepok S, et al. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain 2006;129(Pt 1):200-11
   PubMed Web of Science ®Google Scholar
• Bielekova B, Komori M, Xu Q, et al. Cerebrospinal fluid IL-12p40, CXCL13 and IL-8 as a combinatorial biomarker of active intrathecal inflammation. PLoS One 2012;7(11):e48370
   PubMed Web of Science ®Google Scholar
• Alvarez E, Piccio L, Mikesell RJ, et al. CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions. Mult Scler 2013;19(9):1204-8
   PubMed Web of Science ®Google Scholar
• Romme-Christensen J, Bornsen L, Khademi M, et al. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis. Mult Scler 2013;19(7):877-84
   PubMed Web of Science ®Google Scholar
• Festa ED, Hankiewicz K, Kim S, et al. Serum levels of CXCL13 are elevated in active multiple sclerosis. Mult Scler 2009;15(11):1271-9
   PubMed Web of Science ®Google Scholar
• Ljostad U, Mygland A. CSF B-lymphocyte chemoattractant (CXCL13) in the early diagnosis of acute Lyme neuroborreliosis. J Neurol 2008;255(5):732-7
   PubMed Web of Science ®Google Scholar
• Rupprecht TA, Pfister HW, Angele B, et al. The chemokine CXCL13 (BLC): a putative diagnostic marker for neuroborreliosis. Neurology 2005;65(3):448-50
   PubMed Web of Science ®Google Scholar
• O’Connell KE, Mok T, Sweeney B, et al. The use of cytokine signature patterns: separating drug naive, interferon and natalizumab-treated multiple sclerosis patients. Autoimmunity 2014;47(8):505-11
   PubMed Web of Science ®Google Scholar
• Hagman S, Raunio M, Rossi M, et al. Disease-associated inflammatory biomarker profiles in blood in different subtypes of multiple sclerosis: prospective clinical and MRI follow-up study. J Neuroimmunol 2011;234(1-2):141-7
   PubMed Web of Science ®Google Scholar
• Tomizawa Y, Yokoyama K, Saiki S, et al. Blood-brain barrier disruption is more severe in neuromyelitis optica than in multiple sclerosis and correlates with clinical disability. J Int Med Res 2012;40(4):1483-91
   PubMed Web of Science ®Google Scholar
• Avolio C, Ruggieri M, Giuliani F, et al. Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J Neuroimmunol 2003;136(1-2):46-53
   PubMed Web of Science ®Google Scholar
• Sellebjerg F, Sorensen TL. Chemokines and matrix metalloproteinase-9 in leukocyte recruitment to the central nervous system. Brain Res Bull 2003;61(3):347-55
   PubMed Web of Science ®Google Scholar
• Fainardi E, Castellazzi M, Bellini T, et al. Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis. Mult Scler 2006;12(3):294-301
   PubMed Web of Science ®Google Scholar
• Waubant E, Goodkin D, Bostrom A, et al. IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS. Neurology 2003;60(1):52-7
   PubMed Web of Science ®Google Scholar
• Avolio C, Filippi M, Tortorella C, et al. Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment. Mult Scler 2005;11(4):441-6
   PubMedGoogle Scholar
• Link H, Huang YM. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. J Neuroimmunol 2006;180(1-2):17-28
   PubMed Web of Science ®Google Scholar
• Haertle M, Kallweit U, Weller M, Linnebank M. The presence of oligoclonal IgG bands in human CSF during the course of neurological diseases. J Neurol 2014;261(3):554-60
   PubMed Web of Science ®Google Scholar
• Alvarez-Cermeno JC, Villar LM. Multiple sclerosis: oligoclonal bands-a useful tool to avoid MS misdiagnosis. Nature reviews. Neurology 2013;9(6):303-4
   PubMed Web of Science ®Google Scholar
• Oligoclonal bands and MRI in clinically isolated syndromes: predicting conversion time to multiple sclerosis. J Neurol 2010;257(7):1188-91
   PubMed Web of Science ®Google Scholar
• Correale J, de los Milagros Bassani Molinas M. Oligoclonal bands and antibody responses in multiple sclerosis. J Neurol 2002;249(4):375-89
   PubMed Web of Science ®Google Scholar
• Owens GP, Bennett JL, Lassmann H, et al. Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. Ann Neurol 2009;65(6):639-49
   PubMed Web of Science ®Google Scholar
• Beltran E, Obermeier B, Moser M, et al. Intrathecal somatic hypermutation of IgM in multiple sclerosis and neuroinflammation. Brain 2014;137(Pt 10):2703-14
   PubMedGoogle Scholar
• Villar L, Garcia-Barragan N, Espino M, et al. Influence of oligoclonal IgM specificity in multiple sclerosis disease course. Mult Scler 2008;14(2):183-7
   PubMed Web of Science ®Google Scholar
• Schneider R, Euler B, Rauer S. Intrathecal IgM-synthesis does not correlate with the risk of relapse in patients with a primary demyelinating event. Eur J Neurol 2007;14(8):907-11
   PubMed Web of Science ®Google Scholar
• Garcia-Barragan N, Villar LM, Espino M, et al. Multiple sclerosis patients with anti-lipid oligoclonal IgM show early favourable response to immunomodulatory treatment. Eur J Neurol 2009;16(3):380-5
   PubMed Web of Science ®Google Scholar
• Dobson R, Ramagopalan S, Davis A, Giovannoni G. Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude. J Neurol Neurosurg Psychiatry 2013;84(8):909-14
   PubMed Web of Science ®Google Scholar
• Nilsson P, Larsson EM, Maly-Sundgren P, et al. Predicting the outcome of optic neuritis: evaluation of risk factors after 30 years of follow-up. J Neurol 2005;252(4):396-402
   PubMed Web of Science ®Google Scholar
• Cross AH, Wu GF. Multiple sclerosis: oligoclonal bands still yield clues about multiple sclerosis. Nat Rev Neurol 2010;6(11):588-9
   PubMed Web of Science ®Google Scholar
• Antel JP, Bar-Or A. Do myelin-directed antibodies predict multiple sclerosis? N Engl J Med 2003;349(2):107-9
   PubMed Web of Science ®Google Scholar
• Berger T, Reindl M. Immunopathogenic and clinical relevance of antibodies against myelin oligodendrocyte glycoprotein (MOG) in Multiple Sclerosis. J Neural Transm Suppl 2000(60):351-60
   PubMedGoogle Scholar
• de Seze J, Dubucquoi S, Lefranc D, et al. IgG reactivity against citrullinated myelin basic protein in multiple sclerosis. J Neuroimmunol 2001;117(1-2):149-55
   PubMed Web of Science ®Google Scholar
• Reindl M, Linington C, Brehm U, et al. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study. Brain 1999;122(Pt 11):2047-56
   PubMed Web of Science ®Google Scholar
• Berger T, Rubner P, Schautzer F, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003;349(2):139-45
   PubMed Web of Science ®Google Scholar
• Kuhle J, Pohl C, Mehling M, et al. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med 2007;356(4):371-8
   PubMed Web of Science ®Google Scholar
• Berger T, Reindl M. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med 2007;356(18):1888-9. author reply 1888-1889
   PubMed Web of Science ®Google Scholar
• Quintana FJ, Farez MF, Viglietta V, et al. Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci USA 2008;105(48):18889-94
   PubMed Web of Science ®Google Scholar
• Srivastava R, Aslam M, Kalluri SR, et al. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med 2012;367(2):115-23
   PubMed Web of Science ®Google Scholar
• Nerrant E, Salsac C, Charif M, et al. Lack of confirmation of anti-inward rectifying potassium channel 4.1 antibodies as reliable markers of multiple sclerosis. Mult Scler 2014;20(13):1699-703
   PubMed Web of Science ®Google Scholar
• Brickshawana A, Hinson SR, Romero MF, et al. Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study. Lancet Neurol 2014;13(8):795-806
   PubMed Web of Science ®Google Scholar
• Filippi M, Rocca MA, Lassmann H. KIR4.1: another misleading expectation in multiple sclerosis? Lancet Neurol 2014;13(8):753-5
   PubMed Web of Science ®Google Scholar
• Hedegaard CJ, Chen N, Sellebjerg F, et al. Autoantibodies to myelin basic protein (MBP) in healthy individuals and in patients with multiple sclerosis: a role in regulating cytokine responses to MBP. Immunology 2009;128(1 Suppl):e451-61
   PubMed Web of Science ®Google Scholar
• Elkarim RA, Mustafa M, Kivisakk P, et al. Cytokine autoantibodies in multiple sclerosis, aseptic meningitis and stroke. Eur J Clin Invest 1998;28(4):295-9
   PubMed Web of Science ®Google Scholar
• Watanabe M, Uchida K, Nakagaki K, et al. High avidity cytokine autoantibodies in health and disease: pathogenesis and mechanisms. Cytokine Growth Factor Rev 2010;21(4):263-73
   PubMed Web of Science ®Google Scholar
• Cameron EM, Spencer S, Lazarini J, et al. Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis. J Neuroimmunol 2009;213(1-2):123-30
   PubMed Web of Science ®Google Scholar
• Ligocki AJ, Lovato L, Xiang D, et al. A unique antibody gene signature is prevalent in the central nervous system of patients with multiple sclerosis. J Neuroimmunol 2010;226(1-2):192-3
   PubMed Web of Science ®Google Scholar
• Rosche B, Laurent S, Conradi S, et al. Measles IgG antibody index correlates with T2 lesion load on MRI in patients with early multiple sclerosis. PLoS One 2012;7(1):e28094
   PubMed Web of Science ®Google Scholar
• Reiber H, Ungefehr S, Jacobi C. The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis. Mult Scler 1998;4(3):111-17
   PubMed Web of Science ®Google Scholar
• Brettschneider J, Tumani H, Kiechle U, et al. IgG antibodies against measles, rubella, and varicella zoster virus predict conversion to multiple sclerosis in clinically isolated syndrome. PLoS One 2009;4(11):e7638
   PubMed Web of Science ®Google Scholar
• Simon KC, O’Reilly EJ, Munger KL, et al. Epstein-Barr virus neutralizing antibody levels and risk of multiple sclerosis. Mult Scler 2012;18(8):1185-7
   PubMed Web of Science ®Google Scholar
• Bray PF, Luka J, Bray PF, et al. Antibodies against Epstein-Barr nuclear antigen (EBNA) in multiple sclerosis CSF, and two pentapeptide sequence identities between EBNA and myelin basic protein. Neurology 1992;42(9):1798-804
   PubMed Web of Science ®Google Scholar
• Willis SN, Stadelmann C, Rodig SJ, et al. Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain 2009;132(Pt 12):3318-28
   PubMed Web of Science ®Google Scholar
• Lunemann JD, Edwards N, Muraro PA, et al. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain 2006;129(Pt 6):1493-506
   PubMedGoogle Scholar
• Cepok S, Zhou D, Srivastava R, et al. Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest 2005;115(5):1352-60
   PubMed Web of Science ®Google Scholar
• De Jager PL, Simon KC, Munger KL, et al. Integrating risk factors: HLA-DRB1*1501 and Epstein-Barr virus in multiple sclerosis. Neurology 2008;70(13 Pt 2):1113-18
   PubMed Web of Science ®Google Scholar
• Skorstad G, Vandvik B, Vartdal F, Holmoy T. MS and clinically isolated syndromes: shared specificity but diverging clonal patterns of virus-specific IgG antibodies produced in vivo and by CSF B cells in vitro. Eur J Neurol 2009;16(10):1124-9
   PubMed Web of Science ®Google Scholar
• Lamdhade S, Ashkanani A, Alroughani R. Prevalence of Anti-JC Virus Antibody in Multiple Sclerosis Patients in Kuwait. ISRN Neurology 2014;2014:861091
   PubMedGoogle Scholar
• Marrie RA. When one and one make three: HLA and EBV infection in MS. Neurology 2008;70(13 Pt 2):1067-8
   PubMed Web of Science ®Google Scholar
• Sellebjerg F, Christiansen M, Garred P. MBP, anti-MBP and anti-PLP antibodies, and intrathecal complement activation in multiple sclerosis. Mult Scler 1998;4(3):127-31
   PubMedGoogle Scholar
• Whitaker JN. Myelin encephalitogenic protein fragments in cerebrospinal fluid of persons with multiple sclerosis. Neurology 1977;27(10):911-20
   PubMed Web of Science ®Google Scholar
• Whitaker JN, Lisak RP, Bashir RM, et al. Immunoreactive myelin basic protein in the cerebrospinal fluid in neurological disorders. Ann Neurol 1980;7(1):58-64
   PubMed Web of Science ®Google Scholar
• Lamers KJ, de Reus HP, Jongen PJ. Myelin basic protein in CSF as indicator of disease activity in multiple sclerosis. Mult Scler 1998;4(3):124-6
   PubMedGoogle Scholar
• Barkhof F, Frequin ST, Hommes OR, et al. A correlative triad of gadolinium-DTPA MRI, EDSS, and CSF-MBP in relapsing multiple sclerosis patients treated with high-dose intravenous methylprednisolone. Neurology 1992;42(1):63-7
   PubMed Web of Science ®Google Scholar
• Raphael I, Mahesula S, Kalsaria K, et al. Microwave and magnetic (M(2)) proteomics of the experimental autoimmune encephalomyelitis animal model of multiple sclerosis. Electrophoresis 2012;33(24):3810-19
   PubMed Web of Science ®Google Scholar
• Mahesula S, Raphael I, Raghunathan R, et al. Immunoenrichment microwave and magnetic proteomics for quantifying CD47 in the experimental autoimmune encephalomyelitis model of multiple sclerosis. Electrophoresis 2012;33(24):3820-9
   PubMed Web of Science ®Google Scholar
• Su E, Bell MJ, Kochanek PM, et al. Increased CSF concentrations of myelin basic protein after TBI in infants and children: absence of significant effect of therapeutic hypothermia. Neurocrit Care 2012;17(3):401-7
   PubMed Web of Science ®Google Scholar
• Verbeek MM, De Jong D, Kremer HP. Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases. Ann Clin Biochem 2003;40(Pt 1):25-40
   PubMedGoogle Scholar
• Dutta R, Trapp BD. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology 2007;68(22 Suppl 3):S22-31. discussion S43-54
   PubMed Web of Science ®Google Scholar
• Agius MA, Kirvan CA, Schafer AL, et al. High prevalence of anti-alpha-crystallin antibodies in multiple sclerosis: correlation with severity and activity of disease. Acta Neurol Scand 1999;100(3):139-47
   PubMed Web of Science ®Google Scholar
• Stoevring B, Vang O, Christiansen M. (alpha)B-crystallin in cerebrospinal fluid of patients with multiple sclerosis. Clin Chim Acta 2005;356(1-2):95-101
   PubMed Web of Science ®Google Scholar
• Vojdani A, Vojdani E, Cooper E. Antibodies to myelin basic protein, myelin oligodendrocytes peptides, alpha-beta-crystallin, lymphocyte activation and cytokine production in patients with multiple sclerosis. J Intern Med 2003;254(4):363-74
   PubMed Web of Science ®Google Scholar
• Middeldorp J, Hol EM. GFAP in health and disease. Prog Neurobiol 2011;93(3):421-43
   PubMed Web of Science ®Google Scholar
• Massaro AR, Tonali P. Cerebrospinal fluid markers in multiple sclerosis: an overview. Mult Scler 1998;4(1):1-4
   PubMed Web of Science ®Google Scholar
• Axelsson M, Malmestrom C, Nilsson S, et al. Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis. J Neurol 2011;258(5):882-8
   PubMed Web of Science ®Google Scholar
• Takano R, Misu T, Takahashi T, et al. Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology 2010;75(3):208-16
   PubMed Web of Science ®Google Scholar
• Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 2005;233(1-2):183-98
   PubMed Web of Science ®Google Scholar
• Bartos A, Fialova L, Soukupova J, et al. Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis. J Neurol 2007;254(1):20-5
   PubMed Web of Science ®Google Scholar
• Krishnamoorthy G, Saxena A, Mars LT, et al. Myelin-specific T cells also recognize neuronal autoantigen in a transgenic mouse model of multiple sclerosis. Nat Med 2009;15(6):626-32
   PubMed Web of Science ®Google Scholar
• Norgren N, Sundstrom P, Svenningsson A, et al. Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology 2004;63(9):1586-90
   PubMed Web of Science ®Google Scholar
• Teunissen CE, Iacobaeus E, Khademi M, et al. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology 2009;72(15):1322-9
   PubMed Web of Science ®Google Scholar
• Kuhle J, Plattner K, Bestwick JP, et al. A comparative study of CSF neurofilament light and heavy chain protein in MS. Mult Scler 2013;19(12):1597-603
   PubMed Web of Science ®Google Scholar
• Gunnarsson M, Malmestrom C, Axelsson M, et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol 2011;69(1):83-9
   PubMed Web of Science ®Google Scholar
• Petzold A, Eikelenboom MJ, Keir G, et al. Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study. J Neurol Neurosurg Psychiatry 2005;76(2):206-11
   PubMed Web of Science ®Google Scholar
• Kuhle J, Leppert D, Petzold A, et al. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology 2011;76(14):1206-13
   PubMed Web of Science ®Google Scholar
• Lim ET, Sellebjerg F, Jensen CV, et al. Acute axonal damage predicts clinical outcome in patients with multiple sclerosis. Mult Scler 2005;11(5):532-6
   PubMed Web of Science ®Google Scholar
• Brettschneider J, Petzold A, Junker A, Tumani H. Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis. Mult Scler 2006;12(2):143-8
   PubMed Web of Science ®Google Scholar
• Petzold A, Mondria T, Kuhle J, et al. Evidence for acute neurotoxicity after chemotherapy. Ann Neurol 2010;68(6):806-15
   PubMed Web of Science ®Google Scholar
• Kuhle J, Malmestrom C, Axelsson M, et al. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis. Acta Neurol Scand 2013;128(6):e33-6
   PubMed Web of Science ®Google Scholar
• Gajofatto A, Bongianni M, Zanusso G, et al. Are cerebrospinal fluid biomarkers useful in predicting the prognosis of multiple sclerosis patients? Int J Mol Sci 2011;12(11):7960-70
   PubMed Web of Science ®Google Scholar
• Colucci M, Roccatagliata L, Capello E, et al. The 14-3-3 protein in multiple sclerosis: a marker of disease severity. Mult Scler 2004;10(5):477-81
   PubMed Web of Science ®Google Scholar
• Bartosik-Psujek H, Archelos JJ. Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis and correlate with intrathecal synthesis of IgG. J Neurol 2004;251(4):414-20
   PubMed Web of Science ®Google Scholar
• Terzi M, Birinci A, Cetinkaya E, Onar MK. Cerebrospinal fluid total tau protein levels in patients with multiple sclerosis. Acta Neurol Scand 2007;115(5):325-30
   PubMed Web of Science ®Google Scholar
• Kapaki E, Paraskevas GP, Michalopoulou M, Kilidireas K. Increased cerebrospinal fluid tau protein in multiple sclerosis. Eur Neurol 2000;43(4):228-32
   PubMed Web of Science ®Google Scholar
• Jaworski J, Psujek M, Janczarek M, et al. Total-tau in cerebrospinal fluid of patients with multiple sclerosis decreases in secondary progressive stage of disease and reflects degree of brain atrophy. Ups J Med Sci 2012;117(3):284-92
   PubMed Web of Science ®Google Scholar
• Jimenez-Jimenez FJ, Zurdo JM, Hernanz A, et al. Tau protein concentrations in cerebrospinal fluid of patients with multiple sclerosis. Acta Neurol Scand 2002;106(6):351-4
   PubMed Web of Science ®Google Scholar
• Fiorini M, Zanusso G, Benedetti MD, et al. Cerebrospinal fluid biomarkers in clinically isolated syndromes and multiple sclerosis. Proteomics Clin Appl 2007;1(9):963-71
   PubMed Web of Science ®Google Scholar
• Holtzman DM. CSF biomarkers for Alzheimer’s disease: current utility and potential future use. Neurobiol Aging 2011;32(Suppl 1):S4-9
   PubMedGoogle Scholar
• Stoeck K, Sanchez-Juan P, Gawinecka J, et al. Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldt-Jakob disease and rapid dementias: a longitudinal multicentre study over 10 years. Brain 2012;135(Pt 10):3051-61
   PubMed Web of Science ®Google Scholar
• Kister I, Bacon TE, Chamot E, et al. Natural history of multiple sclerosis symptoms. Int J MS Care 2013;15(3):146-58
   PubMedGoogle Scholar
• Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993;116(Pt 1):117-34
   PubMed Web of Science ®Google Scholar
• Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003;126(Pt 4):770-82
   PubMed Web of Science ®Google Scholar
• Farias AS, Pradella F, Schmitt A, et al. Ten years of proteomics in multiple sclerosis. Proteomics 2014;14(4-5):467-80
   PubMed Web of Science ®Google Scholar
• Del Boccio P, Pieragostino D, Di Ioia M, et al. Lipidomic investigations for the characterization of circulating serum lipids in multiple sclerosis. J Proteomics 2011;74(12):2826-36
   PubMed Web of Science ®Google Scholar
• Quintana FJ, Farez MF, Weiner HL. Systems biology approaches for the study of multiple sclerosis. J Cell Mol Med 2008;12(4):1087-93
   PubMed Web of Science ®Google Scholar
• Han MH, Hwang SI, Roy DB, et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 2008;451(7182):1076-81
   PubMed Web of Science ®Google Scholar
• Rosenling T, Attali A, Luider TM, Bischoff R. The experimental autoimmune encephalomyelitis model for proteomic biomarker studies: from rat to human. Clin Chim Acta 2011;412(11-12):812-22
   PubMed Web of Science ®Google Scholar
• Friese MA, Montalban X, Willcox N, et al. The value of animal models for drug development in multiple sclerosis. Brain 2006;129(Pt 8):1940-52
   PubMedGoogle Scholar
• Raphael I, Mahesula S, Purkar A, et al. Microwave & Magnetic (M(2)) proteomics reveals CNS-specific protein expression waves that precede clinical symptoms of experimental autoimmune encephalomyelitis. Sci Rep 2014;4:6210
   PubMed Web of Science ®Google Scholar
• Bertolotto A, Sala A, Malucchi S, et al. Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies. J Neurol Neurosurg Psychiatry 2004;75(9):1294-9
   PubMed Web of Science ®Google Scholar
• Gerson B, Cohen SR, Gerson IM, Guest GH. Myelin basic protein, oligoclonal bands, and IgG in cerebrospinal fluid as indicators of multiple sclerosis. Clin Chem 1981;27(12):1974-7
   PubMed Web of Science ®Google Scholar
• Lamers KJ, Uitdehaag BM, Hommes OR, et al. The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1988;51(10):1334-7
   PubMed Web of Science ®Google Scholar
• Greene DN, Schmidt RL, Wilson AR, et al. Cerebrospinal fluid myelin basic protein is frequently ordered but has little value: a test utilization study. Am J Clin Pathol 2012;138(2):262-72
   PubMed Web of Science ®Google Scholar
• Celet B, Akman-Demir G, Serdaroglu P, et al. Anti-alpha B-crystallin immunoreactivity in inflammatory nervous system diseases. J Neurol 2000;247(12):935-9
   PubMed Web of Science ®Google Scholar
• Harada A, Oguchi K, Okabe S, et al. Altered microtubule organization in small-calibre axons of mice lacking tau protein. Nature 1994;369(6480):488-91
   PubMed Web of Science ®Google Scholar